Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis
Background: Genetic and experimental studies support a causal involvement of interleukin-6 (IL-6) signaling in atheroprogression. While trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects.
Methods: Leveraging data from 522,681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6 receptor (IL-6R) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization (MR), we assessed its effects on 3,281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3,301). Using mediation MR, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease (CAD), large artery atherosclerotic stroke (LAAS), and peripheral artery disease (PAD). For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1,704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions.
Results: We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 were associated with risk of CAD, LAAS, and PAD with up to 67% of the effects of genetically downregulated IL-6 signaling on these endpoints mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher CXCL10 expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling.
Conclusions: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in three vascular compartments and as such could serve as a promising drug target for atheroprotection.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2023) vom: 28. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prapiadou, Savvina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 26.02.2024 published: Electronic UpdateIn: Circulation. 2023 Dec 28;:. - PMID 38152968 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.03.24.23287543 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355392895 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355392895 | ||
| 003 | DE-627 | ||
| 005 | 20240229163423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.03.24.23287543 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1308.xml |
| 035 | |a (DE-627)NLM355392895 | ||
| 035 | |a (NLM)37034659 | ||
| 035 | |a (PII)2023.03.24.23287543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prapiadou, Savvina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Circulation. 2023 Dec 28;:. - PMID 38152968 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Genetic and experimental studies support a causal involvement of interleukin-6 (IL-6) signaling in atheroprogression. While trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects | ||
| 520 | |a Methods: Leveraging data from 522,681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6 receptor (IL-6R) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization (MR), we assessed its effects on 3,281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3,301). Using mediation MR, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease (CAD), large artery atherosclerotic stroke (LAAS), and peripheral artery disease (PAD). For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1,704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions | ||
| 520 | |a Results: We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 were associated with risk of CAD, LAAS, and PAD with up to 67% of the effects of genetically downregulated IL-6 signaling on these endpoints mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher CXCL10 expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling | ||
| 520 | |a Conclusions: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in three vascular compartments and as such could serve as a promising drug target for atheroprotection | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 4 | |a Mendelian randomization | |
| 650 | 4 | |a atherosclerosis | |
| 700 | 1 | |a Živković, Luka |e verfasserin |4 aut | |
| 700 | 1 | |a Thorand, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a George, Marc J |e verfasserin |4 aut | |
| 700 | 1 | |a van der Laan, Sander W |e verfasserin |4 aut | |
| 700 | 1 | |a Malik, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Herder, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Koenig, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Ueland, Thor |e verfasserin |4 aut | |
| 700 | 1 | |a Kleveland, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Aukrust, Pal |e verfasserin |4 aut | |
| 700 | 1 | |a Gullestad, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Bernhagen, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Pasterkamp, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Hingorani, Aroon D |e verfasserin |4 aut | |
| 700 | 1 | |a Rosand, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Dichgans, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Georgakis, Marios K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2023) vom: 28. März |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.03.24.23287543 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 03 | ||